Phase 2 N=55 Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
Hepatorenal Syndrome
Primary: Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide — 36.0; 11.9; 15.7; 10.5 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=300 Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
Hepatorenal Syndrome
Primary: Percentage of Participants With Verified HRS Reversal — 29.1; 15.8 percentage of participants
Phase 1 N=61 Combination HTNV and PUUV DNA Vaccine
Hantaan Virus Disease, Puumala Virus
Primary: Summary of Solicited Local Adverse Events (AEs) — 8; 11; 12; 9 Participants
Phase 3 N=50 Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Phase 2 N=66 Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome
Hantavirus Infections
Primary: The Proportion of Subjects Who Develop Death, PaO2/FiO2 Ratio Less Than or Equal to 55, Cardiac Index Less Than or Equal to 2.2, Pulseless Electrical Activity…
Phase 3 N=196 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Hepatorenal Syndrome
Primary: Percentage of Participants With Confirmed Hepatorenal Syndrome (HRS) Reversal — 19.6; 13.1 percentage of participants
Phase 1 N=119 HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Phase 2 N=38 Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency
HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 40.0; 60.0; 100.0 percentage of participants
Phase 2 N=130 Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Hemorrhagic Fever With Renal Syndrome
Primary: Number of Participants With Seroconversion of HTNV and PUUV Using PsVNA50 — 1; 1; 1; 2 Participants
Phase 2 N=115 VSV-ZEBOV Geneva Vaccine Trial
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Phase 1 N=48 Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
Hantavirus Pulmonary Infection · Immunisation
Primary: Number of Participants Experiencing Clinical Safety Laboratory Adverse Events — 0; 2; 0; 0 participants
Phase 4 N=40 EBR/GZR for HCV-1b Patients Receiving Hemodialysis
Hepatitis C
Primary: Sustained Virologic Response (SVR12) Rate — 38 Participants
Phase 4 N=10 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
End-Stage Renal Disease · Hepatitis C
Primary: Number of Participants With Grade 3 or Higher Treatment-related Adverse Events as US Department of Health and Human Services Common Terminology of Adverse Events (CTCAE)…
Phase 3 N=68 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
Chronic Hepatitis C · Hepatitis C Virus · Compensated Cirrhosis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment — 94.1 percentage of participants
Phase 4 N=27 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virologic Response at 24 Weeks Following Treatment Completion — 55.6 Percentage of participants
Phase 1 N=5 Viral Kinetics in HCV Clearance in Subjects With Hemophilia
Chronic Hepatitis C · Hemophilia
Primary: Number of Participants With Sustained Virological Response at Week 12 (SVR12) — 2; 2 participants
Phase 4 N=50 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
Chronic Hepatitis C
Primary: Change in Hepatitis C Virus RNA Levels During Phase I — 0.50; 0.70 log(IU/mL) — p=0.54
Phase 2 N=28 Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
SARS-CoV-2 Infection · Acute Kidney Injury
Primary: Change in Whole Blood NAD+ Level — -0.02; 0.06 μg/mL
Phase 4 N=15 Hepatitis C Virus(HCV) Heart and Lung Study
Hepatitis C, Chronic · Heart Failure · Pulmonary Disease, Chronic Obstructive
Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants
Phase 3 N=43 Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
Anemia of Chronic Kidney Disease
Primary: Efficacy Evaluation Through Change in Hemoglobin Levels — 9.56; 9.44; 11.05; 11.11 Hemoglobin levels (g/dL)
Phase 3 N=81 HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment — 39.5; 34.9 percentage of participants — p=0.6746
Phase 4 N=46 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis
Hepatitis Viruses
Primary: Number of Participants With Sustained Virologic Response (SVR12) — 46 Participants
N/A N=1,492 The Etiology of Acute Febrile Illness Requiring Hospitalization
Acute Febrile Illness
Primary: The Etiologies (Bacteria, Viruses, Parasites, Fungi and Others) of Fever Illness Expressed in Percentages of Enrolled Subjects. — 621; 362; 15; 5 Participants
Phase 2 N=278 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Rift Valley Fever
Primary: Safety: All Incidences of Erythema — 15; 10; 0 number of events
N/A N=202 The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis
Renal Artery Obstruction · Hypertension, Renal
Primary: Binary Restenosis Rate — 10.5 Percentage of lesions — p=< 0.0001
N/A N=47 Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
Hypertension
Primary: Adverse Events — 47.8 percentage of participants
Phase 2 N=20 Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
Rift Valley Fever
Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs
N/A N=50 Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation
Uncontrolled Hypertension · Atrial Fibrillation
Primary: Anti-arrhythmic Drug (AAD)-Free Single-procedure Freedom From Atrial Fibrillation Recurrence — 6; 2 recurrences
Phase 3 N=40 Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
Anemia · Renal Failure
Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L
Phase 4 N=4 Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
Hepatitis C · Hemodialysis · Nosocomial Infection
Primary: SVR - Sustained Virologic Response — 3; 0; 1; 0 Participants